Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- L CHANDRASEKARDesignation :- Company Secretary and Compliance Officer Approval Of Resolution Plan By NCLT, Chennai
Approval of Resolution Plan by NCLT, Chennai AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31,2018
AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31,2018 Audited Financial Results For The Year Ended March 31, 2018
Audited financial results for the year ended March 31, 2018 Board Meeting Intimation for Quarter And Year Ended March 31, 2018
ORCHID PHARMA LTDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/08/2018 ,inter alia, to consider and approve Audited Financial Results (both Standalone and Consolidated) of the Company for the quarter (Q4 of FY 2017-18) and year ended 31st March 2018 DISCLOSURE UNDER REGULATION 30 OF THE SEBI(LODR)REGULATIONS,2015
DISCLOSURE UNDER REGULATION 30 OF THE SEBI(LODR)REGULATIONS,2015 Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- L CHANDRASEKARDesignation :- Company Secretary and Compliance Officer Shareholding for the Period Ended June 30, 2018
Orchid Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here